|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1989-12-15
|
|
pubmed:abstractText |
The 62 kDa protein product of the c-myc oncogene (p62 c-myc) is thought to be involved in the control of normal cellular proliferation and differentiation. We have measured oncoprotein levels using a flow cytometric assay in 141 operable breast cancers and have correlated levels with prognostic variables, patient survival and disease free intervals. High levels of p62 c-myc were associated with well differentiated tumours. There was no correlation with tumour DNA index, lymph node or oestrogen receptor status. C-myc oncoprotein levels were not predictive of patient survival or disease free interval. This relationship of oncoprotein levels with tumour histological grade is in keeping with the suggestion that the c-myc oncogene is important in the control of cellular differentiation. The other findings imply that measurement of c-myc oncoprotein levels does not yield useful prognostic information.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3511934,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3545431,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3552016,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3885045,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3902971,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3915782,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-3982504,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-4027160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-4065102,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-5910392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6090941,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6192303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6289129,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6297003,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6332711,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6463648,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6472449,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-6606489,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2679850-698968
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
669-72
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
c-myc oncogene product expression and prognosis in operable breast cancer.
|
|
pubmed:affiliation |
Nottingham City Hospital, UK.
|
|
pubmed:publicationType |
Journal Article
|
